HCPCS Level II code C1717 denotes a non-stranded, high dose rate iridium-192 brachytherapy source billed per source. These radioactive sources are central to HDR brachytherapy treatments used across oncology to deliver localized, high-dose radiation with rapid dose falloff, reducing exposure to surrounding healthy tissue. Nationally, accurate coding for brachytherapy sources matters for clinical documentation, radiation safety compliance, and consistent payment processing for institutional and physician services.

Key payers covered in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the code's clinical role, typical sites of service such as hospital outpatient departments and radiation oncology clinics, and the kinds of materials and supply charges this code represents. The publication summarizes common billing considerations, typical modifiers that may appear on claims (provided in the input), and related administrative issues affecting reimbursement and claim adjudication.

This summary provides benchmarks and policy context relevant to facility billing for HDR brachytherapy supplies, highlights areas where coding clarity supports compliance, and outlines the clinical context for use of C1717. Data not available in the input is noted where applicable in the full publication.